LBL-047

N/A

Report date: 2025/11/27 11:01:57
First In Class

Base Information

Drug NameLBL-047
Drug Alias NameLBL-047DNTH212DNTH-212
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionTumor necrosis factor receptor superfamily member 13B inhibitorsC-Type lectin domain family 4 member C inhibitors
TargetsC-Type lectin domain family 4 member CTumor necrosis factor receptor superfamily member 13B
Therapy Area/IndicationsAutoimmune DiseasesLupus Erythematosus, Systemic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNanjing Leadsbiolabs Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Leadsbiolabs Co LtdDianthus Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesLupus Erythematosus, Systemic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A